Read by QxMD icon Read


Eyal Krispin, Eran Hadar, Rony Chen, Arnon Wiznitzer, Boris Kaplan
OBJECTIVE: We aimed to compare the efficacy of commonly available progesterone preparations for preterm birth prevention. METHODS: A retrospective cohort study of all women treated with progesterone to prevent preterm birth and delivered in a single university-affiliated tertiary medical-center. Four progesterone preparations were compared: vaginal Endometrin 100 mg twice daily, vaginal Crinone 8% gel 90 mg daily, vaginal Utrogestan 200 mg daily, and intramuscular 17α-hydroxyprogesterone caproate (17-OHPC) 250 mg weekly...
April 26, 2018: Journal of Maternal-fetal & Neonatal Medicine
Tim Child, Saoirse A Leonard, Jennifer S Evans, Amir Lass
Vaginal progesterone via capsule, gel or tablet is the most common route for luteal phase support (LPS) in Europe. Although there is a wealth of data comparing products used at other stages of assisted reproductive technology cycles, there is a lack of systematically identified evidence comparing the wide range of vaginal progesterone products. This systematic review queried the MEDLINE, Embase and Cochrane Library databases on 30 June 2016 to identify head-to-head randomized controlled trials (RCTs) comparing the efficacy or safety of vaginal progesterone preparations (Crinone, Cyclogest, Lutigest or Utrogestan Vaginal) for LPS in assisted reproductive technology cycles...
February 22, 2018: Reproductive Biomedicine Online
Tai-Ho Hung, Szu-Fu Chen, Chung-Pu Wu, Meng-Jen Li, Yi-Lin Yeh, T'sang-T'ang Hsieh
INTRODUCTION: Vaginal administration of micronized progesterone (utrogestan capsule, UG) reduces the risk of preterm birth (PTB) in asymptomatic women with a sonographic short cervix at mid-trimester or with a prior history of spontaneous PTB; however, its exact mechanisms remain unclear. We hypothesized that UG limits the inflammatory processes within the gestational tissues and the cervix. METHODS: Fetal membranes and villous tissues were obtained from normal term placentas from women with cesarean delivery before labor onset...
September 2017: Placenta
Xiuxian Zhu, Hongjuan Ye, Yonglun Fu
Progesterone soft capsules (brand name: Utrogestan) were demonstrated to be an effective oral alternative to prevent premature LH surges both in normal-ovulatory and polycystic ovarian syndrome (PCOS) patients. However, its safety in terms of neonatal outcomes is unclear. To evaluate whether Utrogestan use increase the risk of adverse neonatal outcomes compared with short protocol in patients undergoing IVF/ICSI treatments in combination with frozen-thawed embryo transfer (FET), we performed a retrospective analysis including 1008 FET cycles, with embryos originated from either Utrogestan + hMG protocol (n = 499), or short protocol (n = 509), which led to 546 live-born infants...
August 10, 2017: Scientific Reports
Xiuxian Zhu, Hongjuan Ye, Yonglun Fu
OBJECTIVE: To evaluate endocrine characteristics and clinical outcomes in normal ovulatory patients undergoing controlled ovarian hyperstimulation (COH) with the use of a Duphaston and hMG protocol during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatments in combination with frozen-thawed embryo transfer (FET) compared with the characteristics and outcomes of patients undergoing an Utrogestan and hMG protocol. DESIGN: Prospective controlled study...
September 2017: Fertility and Sterility
Lucie Michnova, Jiri Dostal, Milan Kudela, Petr Hamal, Katerina Langova
BACKGROUND AND OBJECTIVE: Luteal phase physiology is distorted by in vitro fertilization (IVF) cycles using gonadotropin-releasing hormone (GnRH) agonists and antagonists, Controlled ovarian hyperstimulation leads to luteal phase defect and for this reason, luteal phase support is now an integral part of IVF/ICSI-ET programs. The support is provided by hCG, progesterone or GnRH-a. This study compared the efficiency, safety and tolerance of two vaginal micronized progesterones, Utrogestan and Crinone 8%...
March 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
L Michnová, J Dostál, K Langová, T Rumpíková, M Kudela
OBJECTIVE: The study was focused on comparison of efficiency, safety and tolerance of vaginal use of micronized progesterone in preparations Utrogestan and Crinone 8%. DESIGN: Prospective randomized study. SETTING: Department of Gynecology and Obstetric, University Hospital, Olomouc, Faculty of Medicine and Dentistry, Palacky University, Olomouc. MATERIAL AND METHODOLOGY: Into a prospective randomized study was, after calculation of 80% of the power of the study, α = 0,05, included 111 women in age between 18-40 with a basal value FSH < 10 IU/l and a normal finding in uteral cavity...
December 0: Ceská Gynekologie
Xiuxian Zhu, Hongjuan Ye, Yonglun Fu
OBJECTIVE: To compare the clinical characteristics in a Utrogestan and hMG protocol with the use of different doses of Utrogestan in normally ovulating women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatments. DESIGN: Prospective controlled study. SETTING: Tertiary-care academic medical center. PATIENT(S): A total of 150 infertile patients undergoing IVF/ICSI treatments. INTERVENTION(S): Utrogestan and hMG were administered simultaneously beginning on cycle day 3...
February 2017: Fertility and Sterility
A Carauleanu, R Socolov, V Rugina, O Gabia, Daniela Mihaela Carauleanu, Ivona Anghlcelache Lupascu, Demetra Socolov
AIM: Fibrocystic mastosis (FCM) is the most frequent benign breast lesion. Most treatments for fibrocystic mastosis are: hormonl, with beneficial results and non-hormonal, with fluctuating results. MATERIAL AND METHODS: A number of 210 cases were studied, which were divided into 7 groups. The study lasted for 9 months and it was carried out on the basis of a personal examination sheet. The following were monitored: age groups, mastodynia, reducing breast nodules, a significant reduction in the volume of the mastosic cysts, reducion of the fibrous tissue, medication tolerance...
April 2016: Revista Medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti Din Iaş̧i
Xiuxian Zhu, Hongjuan Ye, Yonglun Fu
Poor oocyte quality is a main concern for decreased reproductive outcomes in women with polycystic ovarian syndrome (PCOS) during controlled ovarian hyperstimulation (COH). A primary way to improve oocyte quality is to optimize the COH protocol. It was demonstrated that the viable embryo rate per oocyte retrieved in the Utrogestan and hMG protocol, a novel regimen based on frozen-thawed embryo transfer (FET), is statistically higher than that in the short protocol. Thus, a retrospective study was conducted to evaluate the endocrine characteristics and clinical outcomes in PCOS patients subjected to the Utrogestan and hMG protocol compared with those subjected to the short protocol...
July 2016: Medicine (Baltimore)
Arri Coomarasamy, Helen Williams, Ewa Truchanowicz, Paul T Seed, Rachel Small, Siobhan Quenby, Pratima Gupta, Feroza Dawood, Yvonne E Koot, Ruth Bender Atik, Kitty Wm Bloemenkamp, Rebecca Brady, Annette Briley, Rebecca Cavallaro, Ying C Cheong, Justin Chu, Abey Eapen, Holly Essex, Ayman Ewies, Annemieke Hoek, Eugenie M Kaaijk, Carolien A Koks, Tin-Chiu Li, Marjory MacLean, Ben W Mol, Judith Moore, Steve Parrott, Jackie A Ross, Lisa Sharpe, Jane Stewart, Dominic Trépel, Nirmala Vaithilingam, Roy G Farquharson, Mark David Kilby, Yacoub Khalaf, Mariëtte Goddijn, Lesley Regan, Rajendra Rai
BACKGROUND AND OBJECTIVES: Progesterone is essential to maintain a healthy pregnancy. Guidance from the Royal College of Obstetricians and Gynaecologists and a Cochrane review called for a definitive trial to test whether or not progesterone therapy in the first trimester could reduce the risk of miscarriage in women with a history of unexplained recurrent miscarriage (RM). The PROMISE trial was conducted to answer this question. A concurrent cost-effectiveness analysis was conducted...
May 2016: Health Technology Assessment: HTA
Xiuxian Zhu, Xiaole Zhang, Yonglun Fu
A major cause of cycle cancellation during controlled ovarian hyperstimulation (COH) in women undergoing in vitro fertilization (IVF) is the occurrence of premature luteinizing hormone (LH) surges. Steroidal preparations can modulate the secretion of gonadotropins (Gn); however, few studies using progesterone to inhibit the premature LH surges in COH have been published. The purpose of the study was to evaluate the oral delivery of progesterone soft capsules (Utrogestan) to prevent LH surges from the follicular phase and to compare cycle characteristics as well as to evaluate pregnancy outcomes in subsequent frozen-thawed embryo transfer (FET) cycles...
May 2015: Medicine (Baltimore)
V M Frolov, R A Kornienko, V Ia Starzhinskaia, M V Marchenko
The objective of the present study was to evaluate the influence of hormonal therapy used to correct the hormonal status of the pregnant women during different periods of gestation on the development of the nasal obstruction symptoms. A total of 53 case histories of the pregnant women (urban residents) were available for the analysis. In 2012, all the patients were under observation of an obstetrician-gyneciologist based at an outpatient setting. 16 of them (30.2%) suffered stuffness in the nose that was especially well pronounced during the II and III trimesters (37...
2014: Vestnik Otorinolaringologii
B Marinov, A Andreeva, M Cankova
UNLABELLED: In the recent years the rate of preterm deliveries has not been brought down despite of the new therapeutic management and medications. The aim of this scientific report is to share our algorithm of preterm delivery prevention. MATERIALS AND METHODS: Our trial consisted of 23 patients between 26 and 36 weeks of gestation diagnosed with preterm delivery, for a one year period - May 2010 to May 2011. The following therapeutic algorithm was applied: magnesium preparations, B2-mymetics, if no improvement was seen in 24 hour period we continued with Utrogestan, Calcium channel blockers, Indomethacin...
2011: Akusherstvo i Ginekologii︠a︡
Vlatka Tomic, Jozo Tomic, Djurdja Zigmundovac Klaic
The aim of the present study was to compare the efficacy and satisfaction rate of combined therapy of oral micronized progesterone capsules and vaginal progesterone gel versus monotherapy with vaginal progesterone gel in luteal support. A case-control study was performed on a total number of 370 women aged <45 years undergoing IVF-ET treatment. The patients received either combination of Crinone 8% vaginal gel, 90 mg daily dose and Utrogestan oral capsules 3 x 100 mg, or Crinone 8% vaginal gel, 90 mg daily...
December 2011: Gynecological Endocrinology
P Kostova, V Zlatkov
The aim of the present study was to establish the effectiveness of vaginal administration of micronized progesterone at 37 premenopausal women aged between 40-49 years (mean 44.5) with dysfunctional uterine bleeding. All women were subject of classical dilatation and curettage and after that micronized progesterone (Utrogestan) was applied vaginally 3 tablets 2 times per day, starting at 14 day of the menstrual cycle for 12 days. The control examination has been performed after finishing of 6 months therapy...
2009: Akusherstvo i Ginekologii︠a︡
Li-Jung Wang, Fu-Jen Huang, Fu-Tsai Kung, Pin-Yao Lin, Shiuh Young Chang, Kuo-Chung Lan
OBJECTIVE: To compare the efficacy of two vaginal progesterone formulations, Crinone gel and Utrogestan capsules, for luteal phase support in blastocyst stage embryo transfers. MATERIALS AND METHODS: We analyzed 460 consecutive cycles in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-blastocyst transfer (BT) treatment at our institution between January 2004 and December 2007. Patients applied either Crinone 8% vaginal gel (90 mg, once daily) or Utrogestan vaginal capsules (200 mg, four times daily) for luteal supplementation...
December 2009: Taiwanese Journal of Obstetrics & Gynecology
Jerome H Check
Supplementation of progesterone in the luteal phase and continuance of progesterone therapy during the first trimester has been found in several studies to have benefits in promoting fertility, preventing miscarriages and even preventing pre-term labor. Though it can be administered orally, intramuscularly or even sublingually, a very effective route with fewer side effects can be achieved by an intravaginal route. The first vaginal preparations were not made commercially but were compounded by pharmacies. This had the disadvantage of lack of control by the Food and Drug Administration (FDA) ensuring efficacy of the preparations...
August 2009: Therapeutics and Clinical Risk Management
S Bozhinova, P Bozhinov
Epilepsy is a disease, closely connected with sex-hormones and can lead to adverse repercussion on the reproductive health. The ovarial hormones influence excitation of neurocells membranes and have a lot of effects on brain, leading to provoking epileptic activity. The progesteron decrease and the estrogens increase the brain excitation, that's why estrogens (act like a proconvulsant) are proconvulsant and progesteron is anticonvulsant. The aim of this study is to evaluate therapeutic abilities of Utrogestan (micronising progesteron) for treatment of abortions and climacteric amplifications in women with epilepsy...
2005: Akusherstvo i Ginekologii︠a︡
Zh Karag'ozova, T Chernev, D Atanasova, E Pavlova, V Dimitrova, Iu Khranov, S Vragaleva
A retrospective study with 79 pregnant women was conducted. All of them were diagnosed as spontaneous abortion. The patients were separated in two group and the women have been treated in two schemes--51%--Utrogestan and 49%--Utrogestan and Profasi. The medication was applied only into the first trimester of the pregnancy. The duration of the therapy was 15.0 +/- 12.34 days. The mean gestational age in this study was 7.6 +/- 3.0 gestational weeks. Women with a first pregnancy and spontaneous abortion were excluded from the study...
2007: Akusherstvo i Ginekologii︠a︡
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"